Back to top
more

Intuitive Surgical (ISRG)

(Delayed Data from NSDQ)

$486.62 USD

486.62
740,884

+1.86 (0.38%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $487.17 +0.55 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Veeva's Vault CDMS to Unify Clinical Data in Single Platform

Veeva's (VEEV) cloud-based applications' market prospects bright.

    Here's Why You Should Invest in Masimo (MASI) Right Now

    A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.

      ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio

      ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.

        QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers

        Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.

          Cooper's MiSight Lens Effective in Checking Juvenile Myopia

          Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.

            Can Intuitive Surgical (ISRG) Keep the Earnings Surprise Streak Alive?

            Intuitive Surgical (ISRG) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

              Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

              Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

                CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise

                A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.

                  QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio

                  QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.

                    DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand

                    DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.

                      Omnicell Continues to Pursue Buyouts, Costs on the Rise

                      Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.

                        Cardiovascular Systems Portfolio Strong, Competition Rife

                        Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.

                          Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel

                          Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.

                            Veeva Gains as MD&D Companies Pick Its Cloud-Based Services

                            Veeva's (VEEV) focus on cloud-based services is likely to open up substantial opportunities for the company.

                              Pacific Biosciences (PACB) Jumps: Stock Rises 5.4%

                              Pacific Biosciences (PACB) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.

                                Here's Why You Should Invest in Penumbra (PEN) Stock Now

                                The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.

                                  Sreyoshi Mukherjee headshot

                                  3 Stocks to Watch as Bots Take Bigger Strides in US Healthcare

                                  Robotics and mechatronics shape up the U.S. medical industry; three stocks that catch the eye.

                                    Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio

                                    IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.

                                      Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT

                                      Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.

                                        Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio

                                        A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.

                                          Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio

                                          Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.

                                            Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?

                                            Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.

                                              Integra Lifesciences Picked for Healogics iSupply Program

                                              Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.

                                                Varian Up on Tie-Up With Kenya's Mediheal Group of Hospitals

                                                Varian's (VAR) advanced cancer care solution prospects bright in the global market.

                                                  Here's Why You Should Invest in Surmodics (SRDX) Stock Now

                                                  Continuous focus on R&D and a raised guidance for fiscal 2018 make Surmodics (SRDX) a lucrative pick for investors.